Australia's Rhythm Biosciences at nearly 6-month high on multi-year supply agreement

Rhythm Biosciences

03/02/2026 01:33

** Shares of Rhythm Biosciences RHY.AX rise as much as 33.3% to A$0.20, their highest level since August 6, 2025

** The medical diagnostics tech firm secures a multi-year commercial supply agreement executed with U.S.-based Quansys Biosciences for ColoSTAT reagent kit manufacturing

** Agreement provides scalable manufacturing capacity to support ColoSTAT Access Program and commercial rollout, adds co

** About 1.5 million shares change hands, 2.3x the 30-day average

** YTD, stock up 37% year, including the day's move

 (Reporting by Sherin Sunny in Bengaluru)

 ((Sherin.Sunny@thomsonreuters.com))